Percutaneous transluminal coronary angioplasty sirolimus

PCI, percutaneous coronary intervention PES, paclitaxel-eluting stent PTCA, percutaneous transluminal coronary angioplasty FTCA balloon angioplasty rotational atherectomy directional atherectomy, or excimer laser angioplasty SES, sirolimus-eluting stent. 

This chapter focuses on percutaneous transluminal coronary angioplasty (PTCA), provides a summary of the underlying immune activities of the diseased vasculature, and focuses in part on the role of immune and inflammatory mediators in the restenotic process. In addition, the mechanism of action of sirolimus, the drug used in the first successful DES for reduction of restenosis will be highlighted. Finally, the potential role for immune mediators on the overall processes of atherosclerosis will be explored. 

Effects of sirolimus on percutaneous transluminal coronary angioplasty animal models... 

Treatment of CAV consists of percutaneous transluminal coronary angioplasty and stenting (predominantly drug eluting stents), coronary bypass surgery (which is not successful for this disease) and medical therapy (pravastatin, proliferation signal inhibitors sirolimus and everolimus). Definitive therapy for selected patients with end-stage CAV is retransplantation. 

---